Literature DB >> 18203321

Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota.

Floranne C Wilson1, Steven R Ytterberg, Jennifer L St Sauver, Ann M Reed.   

Abstract

OBJECTIVE: To determine the incidence and prevalence of sporadic inclusion body myositis (sIBM) and polymyositis (PM) in a population-based study.
METHODS: Charts of patients with myositis in Olmsted County, Minnesota, USA, from 1981 to 2000 were reviewed.
RESULTS: For sIBM, the age- and sex-adjusted incidence rates per 100,000 were 0.79 (95% confidence interval = 0.24-1.35), and for PM, 0.41 (95% CI 0.08-0.73). The age- and sex-adjusted prevalence rates per 100,000 were 7.06 (95% CI 0.87-13.24) for sIBM and 3.45 (95% CI 0.00-7.35) for PM.
CONCLUSION: The incidence and prevalence rates for sIBM are higher than previously reported.

Entities:  

Mesh:

Year:  2008        PMID: 18203321

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  29 in total

Review 1.  Update on Inclusion Body Myositis.

Authors:  Duaa Jabari; V V Vedanarayanan; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Rheumatol Rep       Date:  2018-06-28       Impact factor: 4.592

2.  Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; Frederick W Miller
Journal:  JAMA       Date:  2011-01-12       Impact factor: 56.272

Review 3.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

4.  Estimating the incidence of connective tissue diseases and vasculitides in a defined population in Northern Savo area in 2010.

Authors:  P Elfving; O Marjoniemi; H Niinisalo; A Kononoff; L Arstila; E Savolainen; J Rutanen; O Kaipiainen-Seppänen
Journal:  Rheumatol Int       Date:  2016-04-06       Impact factor: 2.631

5.  Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Authors:  Jerry R Mendell; Zarife Sahenk; Samiah Al-Zaidy; Louise R Rodino-Klapac; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Natalie Miller; Mehmet Yalvac; Igor Dvorchik; Melissa Moore-Clingenpeel; Kevin M Flanigan; Kathleen Church; Kim Shontz; Choumpree Curry; Sarah Lewis; Markus McColly; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2017-03-06       Impact factor: 11.454

6.  Demographic and clinical features of inclusion body myositis in North America.

Authors:  A David Paltiel; Einar Ingvarsson; Donald K K Lee; Richard L Leff; Richard J Nowak; Kurt D Petschke; Seth Richards-Shubik; Ange Zhou; Martin Shubik; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2015-02-17       Impact factor: 3.217

7.  Familial aggregation of autoimmune disease in juvenile dermatomyositis.

Authors:  Timothy B Niewold; Stephanie C Wu; Molly Smith; Gabrielle A Morgan; Lauren M Pachman
Journal:  Pediatrics       Date:  2011-04-18       Impact factor: 7.124

Review 8.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 9.  Inclusion body myositis: review of recent literature.

Authors:  Steven A Greenberg
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

Review 10.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.